NITI Aayog released the report Roadmap for Building India as a Leading Bioeconomy Powerhouse by 2035 on July 16, 2026. It outlines a mission-mode strategy to expand India’s bioeconomy through targeted financing, biomanufacturing, regulatory reforms and six National BioMissions.
What is the Bioeconomy?
- Meaning: The bioeconomy encompasses economic activities that use biological resources, processes, data and technologies to produce goods and services.
- Sectoral coverage: It extends beyond pharmaceuticals and agriculture to include biofuels, industrial enzymes, biomaterials, bioplastics, alternative proteins, genomics, diagnostics, marine products and biological methods of carbon capture.
- Technological convergence: The emerging bioeconomy is increasingly driven by the convergence of biotechnology with artificial intelligence, robotics, computational biology, digital twins, biosensors and automated biomanufacturing.
India’s Bioeconomy: Present Position
- Expansion: India’s bioeconomy expanded sixteen-fold from approximately $10 billion in 2014 to $195.3 billion in 2025.
- GDP contribution: The sector now contributes around 4.8% of India’s national GDP.
- Major growth drivers: The report attributes this growth to India’s vaccine and generics industry, expansion of biosimilars and biologics, the E20 ethanol-blending programme, industrial fermentation, biotechnology startups and the Contract Research and Manufacturing Services ecosystem.
India’s Existing Strengths
- Pharmaceutical base: India possesses a globally competitive vaccine, generics and biosimilars industry.
- Startup ecosystem: India has more than 10,000 biotechnology startups; another section of the report places the number at nearly 12,000.
- Manufacturing infrastructure: India has more than 700 USFDA-approved manufacturing plants.
- Public research institutions: India has strong research institutions under the Department of Biotechnology, Biotechnology Research and Innovation Council, CSIR, ICMR, ICAR and DST, along with institutions such as IISc, IITs and IISERs.
- BIRAC network: The Biotechnology Industry Research Assistance Council-supported innovation network covers thousands of innovators and approximately 100 incubators.
- Biodiversity advantage: India possesses significant agricultural, microbial, faunal and marine biodiversity.
- Industrial capacity: India has growing capabilities in biopharmaceutical manufacturing, biofuels, industrial enzymes and contract research.
Sector-wise Projections for 2035
- BioIndustrial sector: The sector is projected to reach $318 billion by 2035.
- BioPharma sector: The sector is projected to reach $228 billion by 2035.
- BioAgriculture sector: The sector is projected to reach $90 billion by 2035.
- BioIT and research: The segment is projected to reach $55 billion by 2035.
- Export target: The roadmap seeks biotechnology exports exceeding $100 billion by 2035.
- Globally competitive companies: It also envisages the creation of at least 15 globally competitive biotechnology companies.
- Important qualification: These figures are projections in a strategic roadmap and should not be treated as existing budgetary commitments or guaranteed economic outcomes.
From BioE3 Policy to Mission-Mode Execution
- Existing policy framework: The Biotechnology for Economy, Environment and Employment Policy, or BioE3 Policy, provides the overarching framework for high-performance biomanufacturing.
- Purpose of the roadmap: The roadmap seeks to convert the broad BioE3 framework into time-bound implementation.
- Central argument: Scientific research alone will not make India a biotechnology power.
- Required linkages: Research must be connected with financing, pilot-scale facilities, commercial manufacturing, regulation, skilled personnel, biological data, intellectual property protection and assured markets.
- Implementation structure: The proposed National BioMissions would receive ten-year implementation plans, ring-fenced budgets, designated lead agencies, measurable outcomes and real-time monitoring.
- Delivery model: These missions are intended to function as integrated delivery platforms rather than conventional grant-based research programmes.
₹50,000-Crore BioEconomy Growth Fund
- Proposal: The report recommends establishing a ₹50,000-crore BioEconomy Growth Fund for the period 2026–2035.
- Principal objective: The fund would address the biotechnology sector’s “valley of death”—the financing gap between a successful proof of concept and commercial-scale manufacturing.
- Nature of the problem: Biotechnology projects normally require long development periods, expensive validation, clinical or field trials, regulatory approval and specialised manufacturing facilities.
- Investor hesitation: Conventional investors frequently consider these projects too risky, particularly after early-stage research but before predictable commercial revenues emerge.
Proposed Financial Instruments
- Blended finance: The fund would combine public and private capital to reduce investment risks.
- Viability-gap funding: Financial assistance would be provided to commercially promising projects that are not initially financially viable.
- Milestone-based grants: Funding would be released on the achievement of specified research, validation or commercialisation milestones.
- Catalytic equity: Public investment could absorb part of the early risk and attract additional private capital.
- Long-term infrastructure financing: The fund would support biofoundries, Good Manufacturing Practice facilities and specialised manufacturing infrastructure.
- Regulatory and commercial support: Assistance would be provided for regulatory readiness and commercial scale-up.
Priority Areas
- Advanced therapeutics: The fund would support emerging cell, gene and other advanced therapies.
- Biologics: Support would extend to vaccines, biosimilars and other biological medicines.
- Diagnostics and medical technology: Indigenous diagnostics, medical devices and health technologies would receive support.
- Synthetic biology: Financing would support engineered biological systems and synthetic-biology products.
- Precision fermentation: The fund would support fermentation-based production of proteins, chemicals, enzymes and other products.
- Biomaterials: Financing would cover biological alternatives to conventional industrial materials.
- Industrial biomanufacturing: The fund would support the commercial-scale production of biological products.
Link with the RDI Scheme
- Institutional arrangement: The fund is proposed as a Special Purpose Fund under the Anusandhan National Research Foundation–Research, Development and Innovation framework.
- Broader framework: It would complement the ₹1-lakh-crore RDI Scheme intended to mobilise private-sector research and deep-technology investment.
Proposed PLI for Biomanufacturing
- Separate recommendation: The report recommends a dedicated production-linked incentive scheme for biomanufacturing.
- Potential coverage: The scheme could cover advanced biologics, biosimilars, industrial enzymes, fermentation-based products and bio-based intermediates.
- Expected benefits: The scheme would improve cost competitiveness, reduce dependence on imported inputs and embed India within high-value global supply chains.
Six Proposed National BioMissions
GeneIndia
- Mission objective: GeneIndia would build an affordable and domestically anchored cell and gene-therapy ecosystem.
- Programme convergence: It would integrate GenomeIndia, the National Policy for Rare Diseases, DBT’s UMMID programme and ICMR–DBT gene-therapy guidelines.
Genomic Database
- Dataset expansion: The mission proposes expanding India’s genomic reference datasets first to 50,000 and subsequently to one lakh individuals.
- Expected benefit: The enlarged database would improve the identification of disease-causing genetic variants across India’s diverse population.
Screening and Technology Hubs
- Newborn screening: The mission proposes the progressive expansion of newborn screening.
- National technology hubs: It recommends creating three to five national technology hubs.
- Technology areas: These hubs would develop capabilities in viral vectors, non-viral delivery, CRISPR, base editing and RNA therapeutics.
- Clinical infrastructure: Selected rare-disease Centres of Excellence would be upgraded into clinical units with GMP-compliant cell-processing facilities and long-term patient-monitoring systems.
Priority Diseases
- Haemophilia: The initial disease priorities could include haemophilia.
- Spinal muscular atrophy: The mission could prioritise the development of treatment for spinal muscular atrophy.
- Beta-thalassaemia: Indigenous gene-therapy solutions could be developed for beta-thalassaemia.
- Sickle-cell disease: The mission could support advanced treatment for sickle-cell disease.
- Lysosomal storage disorders: Selected lysosomal storage disorders could also receive priority.
Proposed Timeline
- By 2030: The roadmap seeks multiple clinical trials and the establishment of a national outcomes registry.
- By 2033: It seeks to take a home-grown vector-based therapy to Phase III clinical trials.
- By 2035: It proposes the approval and large-scale deployment of two affordable indigenous gene therapies.
AgriBio 2.0
Mission objective: AgriBio 2.0 would employ biotechnology to improve farm profitability, food security and climate resilience while reducing excessive dependence on chemical inputs.
Technological Focus
- Gene editing: The mission would use CRISPR-based gene editing to develop improved crop varieties.
- Molecular breeding: Molecular breeding would be employed to accelerate the development of desirable crop traits.
- Genomic selection: Genomic information would be used to select crops with superior characteristics.
- Climate resilience: The mission would develop crops tolerant to drought, heat, salinity and emerging pests.
Biological Farm Inputs
- Biofertilisers: The mission would promote high-quality biofertilisers to improve soil fertility.
- Biopesticides: It would encourage biological alternatives to chemical pesticides.
- Microbial consortia: Beneficial combinations of microorganisms would be used to improve crop productivity and soil health.
- Biostimulants: Biological substances and organisms that improve plant growth would be scaled up.
- Soil-health enhancers: The mission would support products that restore soil quality and biological activity.
Convergence with Existing Programmes
- National Mission for Sustainable Agriculture: AgriBio 2.0 would align biotechnology with climate-resilient agricultural practices.
- Soil Health Card Scheme: Biological inputs could support better nutrient management and soil restoration.
- National Food Security Mission: Biotechnology could contribute to higher and more stable agricultural productivity.
- PM-PRANAM: Biological inputs could help reduce the excessive use of chemical fertilisers.
- Biotech-KISAN: Existing farmer-oriented biotechnology networks would support technology transfer.
- Krishi Vigyan Kendras: KVKs would help undertake field validation and farmer demonstrations.
- Agricultural universities: State agricultural universities would support research, testing and extension.
Production Clusters and Biosafety
- BioInput Production and Innovation Clusters: These clusters would support local production, affordability and quality assurance.
- Need for field validation: Products must be tested for effectiveness before large-scale promotion.
- Need for regulation: Transparent and science-based biosafety regulation would be essential for maintaining farmer and consumer confidence.
BioX Foundry
- Mission objective: BioX Foundry would commercialise innovations in synthetic biology and industrial biotechnology.
- Existing foundation: It would build on the National Biofoundry Network, Bio-AI Hubs and Biomanufacturing Hubs envisaged under the BioE3 Policy.
Design–Build–Test–Learn Model
- Design: Biological systems and products would be designed using computational methods and artificial intelligence.
- Build: The proposed biological system would be physically constructed in specialised laboratories.
- Test: The performance of the constructed system would be experimentally evaluated.
- Learn: The test results would be used to improve the next version of the product or process.
- Expected advantage: AI, laboratory robotics, biosensors and computational metabolic modelling could sharply shorten product-development cycles.
Priority Products
- Industrial enzymes: The mission would support sustainable enzymes used in manufacturing.
- Biomaterials: Biological alternatives to conventional industrial materials would be developed.
- High-value biochemicals: Synthetic biology would be used to produce specialised chemicals.
- Smart proteins: The mission would promote proteins designed for nutritional, industrial or medical applications.
- Next-generation biopharmaceuticals: Biofoundries would support the development of advanced biological medicines.
Startup and Manufacturing Support
- Shared infrastructure: Startups and researchers would be allowed to test and scale products without independently bearing the full cost of sophisticated infrastructure.
- Startup target: The mission aims to incubate and scale at least 100 high-potential synthetic-biology startups by 2035.
- Manufacturing objective: It seeks to position India as a preferred location for fermentation-based production and contract biomanufacturing.
One Health Grid
- Underlying principle: The One Health Grid recognises the interconnected nature of human, animal, wildlife and environmental health.
- Institutional position: It would become an operational pillar of the National One Health Mission.
Integrated Surveillance
- Human health data: The network would incorporate information from human-disease surveillance systems.
- Animal health data: Veterinary surveillance systems would contribute information on livestock and animal diseases.
- Wildlife monitoring: Wildlife platforms would help detect pathogens with zoonotic potential.
- Wastewater surveillance: Wastewater monitoring would provide early evidence of circulating pathogens and antimicrobial resistance.
- Environmental laboratories: Environmental surveillance would help identify biological risks emerging from water, soil and ecosystems.
- Digital integration: These data streams would be connected through an interoperable national surveillance network.
Technology and Response Capacity
- AI-assisted analytics: Artificial intelligence would support disease prediction and risk assessment.
- Risk scoring: Integrated information would help identify zoonotic threats, antimicrobial-resistance hotspots and climate-linked health risks.
- High-containment laboratories: The grid would strengthen linkages among 23 BSL-3/4 laboratories.
- State-level network: State diagnostic laboratories, veterinary facilities, forest networks and district rapid-response units would be connected with national facilities.
- Biosensor deployment: Biosensors could be placed across livestock farms, slaughterhouses, water bodies and wastewater systems for real-time pathogen detection.
Community Participation
- ASHAs: Accredited Social Health Activists could contribute community-level health information.
- Pashu Sakhis: Pashu Sakhis could support animal-disease reporting at the village level.
- Forest personnel: Forest workers could provide early warnings concerning wildlife health and zoonotic threats.
- Outcome by 2035: The mission seeks a unified national early-warning and rapid-response architecture for infectious diseases and biological threats.
Marine Biotechnology Mission
Mission objective: The mission would use India’s coastline, Exclusive Economic Zone and marine biodiversity to develop seaweed-based products, nutraceuticals, marine enzymes, biopolymers, specialty chemicals and algae-derived bioenergy.
Importance of Seaweed
- Resource efficiency: Seaweed cultivation does not require agricultural land, freshwater, fertilisers or pesticides.
- Species diversity: India possesses around 844 recorded seaweed species.
- Commercial potential: Nearly 60 Indian seaweed species are considered commercially valuable.
- Agar: Seaweed can be used to produce agar for food, laboratory and industrial applications.
- Alginate: Seaweed-derived alginate has applications in food, pharmaceuticals and industry.
- Carrageenan: Carrageenan is used as a thickening and stabilising agent.
- Biostimulants: Seaweed-based biostimulants can improve crop growth and stress tolerance.
- Biomaterials: Seaweed can provide renewable raw material for sustainable industrial products.
Policy and Infrastructure Convergence
- Blue Economy framework: The mission would align marine biotechnology with India’s broader Blue Economy objectives.
- Pradhan Mantri Matsya Sampada Yojana: Seaweed cultivation and coastal infrastructure could be supported through PMMSY.
- Deep Ocean Mission: Marine bioprospecting and ocean research under the Deep Ocean Mission could support the identification of commercially useful biological resources.
- Marine-bioresource hubs: Integrated hubs would connect marine research with processing and product development.
- Pilot biorefineries: Pilot facilities would convert seaweed and other marine biomass into multiple value-added products.
Livelihood and Environmental Dimensions
- Coastal employment: Community-led seaweed cultivation could generate supplementary livelihoods.
- Women’s participation: Seaweed farming could create income opportunities for coastal women.
- Export potential: Marine biotechnology could increase India’s exports of value-added marine products.
- Climate-compatible development: Seaweed-based economic activities could support low-input and environmentally sustainable growth.
- Environmental safeguard: Ecological carrying capacity and the protection of sensitive coastal ecosystems would remain essential.
BioPharmaNext
Mission objective: BioPharmaNext would move India from a predominantly generics-oriented pharmaceutical model towards innovation-led biopharmaceutical production.
Priority Products
- Vaccines: India’s existing vaccine-manufacturing capabilities would be expanded into newer technology platforms.
- Next-generation biosimilars: The mission would promote affordable versions of complex biological medicines.
- Monoclonal antibodies: Domestic capabilities would be strengthened for developing and manufacturing monoclonal antibodies.
- Long-acting biologics: The mission would support biological medicines designed to remain effective for longer periods.
- Drug conjugates: It would promote therapies that combine biological targeting mechanisms with active drugs.
- AI-designed therapeutics: Artificial intelligence would be used to identify and optimise potential medicines.
Global Opportunity
- Rising importance of biologics: Biologics are expected to constitute a growing share of global medicines.
- Patent expirations: Major biopharmaceutical patents are approaching expiry, creating opportunities for biosimilars and new biological products.
Infrastructure and Innovation
- AI-enabled drug discovery: National platforms would use artificial intelligence to accelerate the identification of drug candidates.
- National bio-compute infrastructure: High-performance computing would support genomic analysis, molecular simulation and drug design.
- Automated protein engineering: Robotics and AI could accelerate the design and testing of therapeutic proteins.
- Biosensor-based quality systems: Biosensors could improve real-time monitoring and quality control during manufacturing.
- Clinical-trial design: Advanced data analysis could improve patient selection and trial efficiency.
- Bioinnovation Clusters: The report proposes at least five integrated Bioinnovation Clusters.
- Shared facilities: These clusters would include Good Laboratory Practice and Good Manufacturing Practice facilities.
- High-performance computing centres: Dedicated computing centres would support AI-enabled biotechnology research.
- Shared manufacturing infrastructure: Startups and smaller companies would receive access to advanced production facilities.
Regulatory and Market Support
- Regulatory sandbox: A specialised sandbox would enable controlled and time-bound testing of innovative biological products.
- Clinical-trial network: India’s network of accredited clinical-trial sites would be expanded.
- Public procurement: Preference could be provided to indigenous biologics through government procurement.
- Faster listing pathway: Domestic biologics could receive a faster pathway for market listing.
Relationship with GeneIndia
- BioPharmaNext: The mission would focus on affordable biologics and global-scale manufacturing and supply.
- GeneIndia: The mission would focus on curative cell and gene therapies.
- Complementarity: Together, the two missions would strengthen both mainstream biopharmaceutical manufacturing and frontier therapeutic innovation.
Governance Reforms
Empowered Committee on National BioMissions
- Purpose: The committee would align national priorities, budgets and implementation across different Ministries and departments.
- Monitoring role: It would establish performance indicators and review progress under each BioMission.
- Coordination role: It would reduce fragmentation and facilitate faster cross-ministerial decisions.
National BioData Council
- Purpose: The council would establish standards for secure, interoperable and ethically governed biological data.
- Data sovereignty: It would help protect Indian biological and health data.
- Innovation role: Secure data-sharing frameworks would support AI-enabled research and product development.
BioEconomy Investment and Policy Forum
- Purpose: The forum would connect government, industry, investors and research institutions.
- Investment alignment: It would direct public and private investment towards national bioeconomy priorities.
- Risk reduction: The forum could help design mechanisms for de-risking biotechnology investments.
Bio-IP and Innovation Evaluation Agency
- Purpose: The agency would support patenting, intellectual-property valuation, licensing and technology transfer.
- Startup support: It would help biotechnology startups navigate domestic and international patent systems.
- Commercialisation: Standardised IP valuation could improve access to finance and industry partnerships.
Regulatory Reforms
- Present problem: Biotechnology regulation remains fragmented across multiple agencies and often involves lengthy approval processes.
- Risk-based pathways: The roadmap recommends differentiated regulation based on the nature and risk profile of the technology.
- Time-bound approvals: Clearly defined timelines would reduce uncertainty for researchers, startups and investors.
- Regulatory sandbox: A controlled pathway would be established for testing near-market innovations.
- Regulatory Reform Task Force: A standing task force would coordinate reform across biotechnology-related agencies.
- Institutional coordination: The regulatory functions of CDSCO, RCGM, GEAC, FSSAI and the National Biodiversity Authority would require better coordination.
Modernisation of CDSCO
- Real-world evidence: Regulatory decisions could use evidence generated from the actual use of approved products.
- Decentralised trials: Clinical trials could use digitally connected and geographically distributed models.
- Non-animal testing: New approach methodologies could supplement or replace conventional animal testing where scientifically appropriate.
- Data integrity: Stronger systems would be needed to maintain the quality, reliability and traceability of regulatory data.
- International alignment: India’s regulatory standards would be brought closer to international quality systems.
Biotechnology Patents
- Legal clarity: The report recommends greater clarity in the application of patent exclusions to biotechnology inventions.
- National Bio-IP Repository: A national repository would help record, manage and commercialise Indian biotechnology intellectual property.
- IP-backed investment: Better valuation of biotechnology patents could enable intellectual property to be used for raising finance.
Talent and Institutional Capacity
- Existing employment: India’s biotechnology sector employs more than 3.3 million professionals.
- Researcher density: India has approximately 259 researchers per million people.
- STEM enrolment: Only 25.6% of higher-education enrolment is in science, technology, engineering and mathematics.
- Advanced-skill gap: The report identifies a shortage of researchers and professionals in frontier biotechnology fields.
Recommended Interventions
- Undergraduate education: Biotechnology curricula should be strengthened and aligned with emerging industry requirements.
- PhD programmes: India should expand high-quality doctoral research in frontier biotechnology areas.
- Postdoctoral programmes: Better postdoctoral opportunities would strengthen the advanced-research pipeline.
- Competitive fellowships: Internationally competitive research fellowships would help attract and retain scientific talent.
- Laboratory immersion: Students should receive greater exposure to hands-on experimental and manufacturing environments.
- Diaspora scientists: Re-entry pathways should encourage Indian scientists working abroad to return.
- Artificial intelligence: Biotechnology training should include AI-enabled biological research.
- Bioinformatics: Researchers should be trained in the computational analysis of biological data.
- Regulatory science: India needs more specialists capable of evaluating advanced biological products.
- Robotics: Automated laboratories and manufacturing systems require trained professionals in robotics.
- Advanced manufacturing: Skills must extend beyond laboratory research to commercial-scale biomanufacturing.
- Entrepreneurship: Incubation, mentorship and postdoctoral entrepreneurship programmes would help convert research into enterprises.
Global Approaches and Lessons for India
- United States: The United States follows a whole-of-government approach focused on domestic biomanufacturing, supply-chain resilience and coordination across health, agriculture, energy and security.
- European Union: The European Union connects biotechnology with industrial competitiveness, climate policy, the circular economy and regional implementation.
- China: China follows a plan-led model based on large-scale industrialisation, regional pilot zones, supply-chain security and the integration of biosecurity with economic policy.
- Australia: Australia emphasises translational infrastructure, clinical-trial networks, intellectual-property protection, research-industry collaboration and global integration.
- Common lesson: Global leadership does not emerge from isolated research expenditure.
- Integrated ecosystem: Research must be linked with biomanufacturing, finance, regulation, skills, data infrastructure, standards and market access.
- Digital bio-infrastructure: AI-enabled design platforms, automated bioreactors, computational biology and biosensor-based quality systems are becoming strategic national assets.
Significance for India
- Economic diversification: Biotechnology can create high-value manufacturing, exports and skilled employment.
- Health security: Domestic capabilities in vaccines, biologics, diagnostics and gene therapies can reduce external dependence.
- Agricultural resilience: Climate-resilient crops and quality bio-inputs can improve productivity while protecting soil health.
- Environmental sustainability: Biological production can support cleaner chemicals, biomaterials, biofuels and circular manufacturing.
- Strategic autonomy: Domestic capacity in enzymes, reagents, biological data and advanced therapeutics can strengthen critical supply chains.
- Inclusive development: Bio-input clusters, seaweed farming and decentralised biomanufacturing can generate rural and coastal livelihoods.
- Global leadership: Affordable biological products can extend India’s role from the “pharmacy of the world” to an originator of frontier innovations.
Major Challenges
- Mid-stage financing: Biotechnology companies face difficulty in raising capital between proof-of-concept development and commercial manufacturing.
- Regulatory fragmentation: Multiple regulatory authorities increase uncertainty and approval timelines.
- Scale-up infrastructure: India has limited GMP and GLP facilities for converting laboratory innovations into market-ready products.
- Import dependence: The sector depends on imported raw materials, reagents, enzymes and specialised equipment.
- Clinical-trial capacity: Limited trial networks constrain the development of advanced therapeutics.
- Fragmented data: Biological, clinical and disease data remain dispersed across institutions and platforms.
- Talent shortage: India lacks sufficient regulatory scientists, computational biologists and advanced manufacturing specialists.
- Low-cost imports: Cheap biotechnology inputs and products from other countries could weaken domestic manufacturing.
- Talent migration: Skilled researchers may move to countries offering better laboratories, funding and commercial opportunities.
- Biosecurity risks: Advanced biotechnology can create risks involving accidental release, misuse and dual-use research.
Way Forward
- Biosafety: Rapid innovation must be accompanied by strong scientific assessment of risks to human, animal and environmental health.
- Bioethics: Gene editing, genomic databases and advanced therapies require clear ethical standards and institutional oversight.
- Data privacy: Biological and health data must be protected through consent-based, secure and accountable governance.
- Biodiversity conservation: Commercial use of biological resources should not damage ecosystems or encourage unsustainable extraction.
- Benefit-sharing: Communities that conserve biological resources should receive a fair share of the economic benefits generated from them.
- Centre–State coordination: Effective implementation will require cooperation because health, agriculture, industrial infrastructure and local regulation involve multiple levels of government.
- Outcome-based monitoring: Each BioMission should have measurable annual indicators.
- Commercialisation indicators: Monitoring should track the number of products successfully commercialised.
- Investment indicators: Evaluation should measure the amount of private investment mobilised through public support.
- Regulatory indicators: Approval timelines should be tracked to determine whether regulatory reforms are producing results.
- Trade indicators: Export value and import substitution should be measured.
- Environmental indicators: The ecological performance of biotechnology products and production systems should be assessed.
- Employment indicators: The number, quality and geographical distribution of jobs created should be monitored.
- Implementation risk: Without outcome-based monitoring, the proposed missions could reproduce the fragmentation that the roadmap seeks to overcome.
Cost of Inaction
- Economic opportunity: Delayed action could prevent India from benefiting from one of the fastest-growing deep-technology sectors.
- National security: Continued dependence on other countries for vaccines, therapeutics, food technologies and biodefence products could create strategic vulnerabilities.
- Viksit Bharat objectives: Failure to expand biotechnology could weaken progress towards the envisaged $30-trillion economy and associated employment creation.
- Global leadership: India could lose market opportunities, investment and scientific talent to countries moving faster in biotechnology.
- Environmental consequences: Slow adoption of biological manufacturing and climate-resilient agriculture could delay green industrial transformation.
- Employment loss: Failure to implement the roadmap could prevent the creation of millions of high-value jobs.